Modified immune cells for adults with leukemia or lymphoma who can't have chemo
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new immune cell treatment (called CAR-T) that has been modified to help the cells stay active longer. It is designed for adults with B-cell leukemia or lymphoma who cannot tolerate strong chemotherapy, offering a potentially gentler option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have B-cell acute lymphoblastic leukemia or lymphoma and cannot get intensive chemotherapy.
- Your cancer cells test positive for a protein called CD19.
- You are healthy enough in daily activities (ECOG score 0–2), and your heart, lungs, liver, and kidneys are working well enough for treatment.
- Women who can have children must not be pregnant and must use birth control for at least a year after the infusion; men with partners who can have children must use contraception for at least a year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of immune therapy called CAR-T cells, which are made from your own blood cells to find and attack cancer. It is for adults with leukemia or lymphoma that has come back or is hard to treat.
This trial tests a new type of immune cell therapy called CAR-T cells that are designed to find and destroy cancer cells with the CD19 or CD22 markers. The goal is to see if this experimental treatment can help people with B-cell acute lymphoblastic leukemia or non-Hodgkin's lymphoma when other treatments haven't worked.
This trial tests a new type of immune cell therapy (CAR-T) that targets two proteins on cancer cells—CD19 and CD22—to treat lymphoma or leukemia that has come back or not responded to standard treatment. It aims to see if this two-target approach works better.
This study tests a new type of CAR-T cell therapy designed to treat certain blood cancers (like leukemia, lymphoma, or multiple myeloma) that have come back or not responded to standard treatment. The cells are enhanced with IL-15 to help them work better.
This trial tests a new way to treat B-cell acute lymphoblastic leukemia (B-ALL). The treatment takes your own immune cells, changes them to fight cancer, and then gives them back to you. The goal is to kill leukemia cells and help you go into remission.
This trial tests a new type of CAR-T cell therapy for people with B-cell acute lymphoblastic leukemia that has returned or not responded to standard treatment. The CAR-T cells are made from a donor and modified to target the CD19 protein on leukemia cells.
Hear when a new B Lymphoblastic Leukemia/Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.